soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results Oral Semaglutide Reduces CV Events
Description
GLP1 Medication Bottom Line GLP-1 receptor agonists are not a trend or a celebrity weight loss shortcut
Statistical analysis Statistical analyses were performed by one-way ANOVA followed by Bonferronis post-test for multiple comparisons, as appropriate
Both semaglutide and tirzepatide have potential side effects, but users have reported positive experiences overall
The troglitazone induces cytochrome P450, leading to hepatotoxic reactive metabolites
